Pediatric Myasthenia gravis: Rarity, Triggers, and Access to Therapies

In the second part of this recent interview, Jonathan Strober, MD, a pediatric neurologist specializing in neuromuscular disorders at the University of California, san Francisco, and Benioff Children’s Hospital, addresses why myasthenia gravis is so rare in pediatric patients and discusses disease triggers in this group. He also explains the importance of regulatory approval and insurance coverage for these patients, noting that without approval, access to needed therapies might potentially be limited.

Revisit part 1 of this interview to learn more about the investigation of nipocalimab and extended treatment intervals in pediatric myasthenia gravis.